EVANGELOS TSIAMBAS

Dr. EVANGELOS TSIAMBAS


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Gene
Verified
Journal Article
Closed access
VPVasileios Papanikolaou
Vasileios Papanikolaou
ACAris Chrysovergis
Aris Chrysovergis
VRVasileios Ragos
Vasileios Ragos
ETEVANGELOS TSIAMBAS
EVANGELOS TSIAMBAS
SKSpyros Katsinis
Spyros Katsinis
NMNicholas Mastronikolis
Nicholas Mastronikolis

1 August 2016 in Pathology - Research and Practice
Verified
Journal Article
Closed access
ETEVANGELOS TSIAMBAS
EVANGELOS TSIAMBAS
ALAlicia Y Lefas
Alicia Y Lefas
SGStavros N Georgiannos
Stavros N Georgiannos
VRVasileios Ragos
Vasileios Ragos
PFPanagiotis P Fotiades
Panagiotis P Fotiades
KSKonstantinos Syrigos
Konstantinos Syrigos

29 April 2024 in Molecular Biology Reports
Verified
Journal Article
Open access
PDF file
NMNicholas S. Mastronikolis
Nicholas S. Mastronikolis
ADAlexander Delides
Alexander Delides
EKEfthymios Kyrodimos
Efthymios Kyrodimos
Zoi PiperigkouZoi Piperigkou
Zoi Piperigkou
DSDespoina Spyropoulou
Despoina Spyropoulou
Nikos KaramanosNikos Karamanos
Nikos Karamanos
The incidence of head and neck cancer (HNC), constituting approximately one in ten cancer cases worldwide, affects approximately 644,000 individuals annually. Managing this complex disease involves various treatment modalities such as systemic therapy, radiation, and surgery, particularly for patients with locally advanced disease. HNC treatment necessitates a multidisciplinary approach due to alterations in patients’ genomes affecting their functionality. Predominantly, squamous cell carcinomas (SCCs), the majority of HNCs, arise from the upper aerodigestive tract epithelium. The epidemiology, staging, diagnosis, and management techniques of head and neck squamous cell carcinoma (HNSCC), encompassing clinical, image-based, histopathological and molecular profiling, have been extensively reviewed. Lymph node metastasis (LNM) is a well-known predictive factor for HNSCC that initiates metastasis and significantly impacts HNSCC prognosis. Distant metastasis (DM) in HNSCC has been correlated to aberrant expression of cancer cell-derived cytokines and growth factors triggering abnormal activation of several signaling pathways that boost cancer cell aggressiveness. Recent advances in genetic profiling, understanding tumor microenvironment, oligometastatic disease, and immunotherapy have revolutionized treatment strategies and disease control. Future research may leverage genomics and proteomics to identify biomarkers aiding individualized HNSCC treatment. Understanding the molecular basis, genetic landscape, atypical signaling pathways, and tumor microenvironment have enhanced the comprehension of HNSCC molecular etiology. This critical review sheds light on regional and distant metastases in HNSCC, presenting major clinical and laboratory features, predictive biomarkers, and available therapeutic approaches.

1 May 2007 in Pancreatology
Verified
Journal Article
Closed access
ETEVANGELOS TSIAMBAS
EVANGELOS TSIAMBAS
AKAndreas Karameris
Andreas Karameris
DTDina G. Tiniakos
Dina G. Tiniakos
PKPetros Karakitsos
Petros Karakitsos
To co-evaluate topoisomerase IIa (Topo IIa) protein expression and gene status in pancreatic ductal adenocarcinoma, determining the potential prognostic impact of its alterations. Using tissue microarrays, 50 sporadic, primary pancreatic ductal adenocarcinomas were cored twice and re-embedded into one paraffin block with a core diameter of 1 mm. Immunohistochemistry and chromogenic in situ hybridization were performed in serial tissue sections for the detection of protein expression levels, chromosome 17 and Topo IIa gene status, respectively. Finally using a semi-automated image analysis system we evaluated the levels of protein expression. A significant proportion of the tumors showed Topo IIa overexpression (32/50 or 64%). Gene amplification and deletion were detected in 9 and 4 cases, respectively, associated with protein overexpression. Aneuploidy regarding chromosome 17 was observed in 19/50 tumors and correlated with poor survival rate (Cox regression test: p = 0.001). Topo IIa protein expression was strongly correlated with stage (p = 0.021) and grade (p = 0.034). Topo IIa gene amplification correlates with protein overexpression, but not vice versa. This is a crucial observation for the application of targeted chemotherapies, such as anthracyclines, only in subgroups of patients, according to molecular deregulation criteria and not only to immunohistochemical results. Also, chromosome 17 and not Topo IIa gene instability can be used as a potential independent prognostic factor.

11 May 2010 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ETEVANGELOS TSIAMBAS
EVANGELOS TSIAMBAS
SGStavros N. Georgiannos
Stavros N. Georgiannos
NSNikolaos Salemis
Nikolaos Salemis
DADespoina Alexopoulou
Despoina Alexopoulou
SLSofia Lambropoulou
Sofia Lambropoulou
SDSpyridon Dourakis
Spyridon Dourakis

1 March 2008 in The Journal of Laryngology & Otology
Verified
Journal Article
Closed access
PDF file
DAD Andressakis
D Andressakis
ALA C Lazaris
A C Lazaris
ETEVANGELOS TSIAMBAS
EVANGELOS TSIAMBAS
NKN Kavantzas
N Kavantzas
ARA Rapidis
A Rapidis
EPE Patsouris
E Patsouris
Aims: To investigate the potential role of caspase-3 and caspase-8 protein expression in the biological behaviour of tongue squamous cell carcinoma.Materials and methods: We conducted immunohistochemical analyses of 87 specimens of primary tongue squamous cell carcinoma, using monoclonal anti-caspase-3 and anti-caspase-8 antibodies. A digital image analysis assay was also performed in order to evaluate the results.Results: Reduced expression of caspase-8 and -3 proteins was observed in 30/87 (34.5 per cent) and 79/87 (90.5 per cent) cases, respectively. Cox regression analysis showed no prognostic significance for the association between overall protein expression of either marker and survival probability (p = 0.174 for caspase-3; p = 0.608 for caspase-8). Interestingly, the size of the examined tumours was strongly correlated with survival status (p = 0.024).Conclusions: Simultaneous deregulation of caspase-8 and -3 is a frequent event in tongue squamous cell carcinoma. Activation of caspase-3, which is predominantly down-regulated, may be a crucial process for induction of apoptosis and response to therapeutic strategies.